Safety and Efficacy of Aficamten in Patients With Non-obstructive Hypertrophic Cardiomyopathy: A 36-week Analysis From FOREST-HCM

SEQUOIA-HCM: Enhancing Exercise Response in Obstructive Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Baseline Characteristics of Patients in SEQUOIA-HCM: A Phase 3 Trial of Aficamten in Obstructive Hypertrophic Cardiomyopathy

Evaluation of Aficamten in Patients with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy: REDWOOD HCM Cohort 4

Phase 2 Study of Aficamten in Patients With Obstructive Hypertrophic Cardiomyopathy

Withdrawal of Background Standard of Care Medical Therapy in Patients with Obstructive Hypertrophic Cardiomyopathy Treated with Aficamten in REDWOOD HCM OLE

Effects of Omecamtiv mecarbil in heart failure with reduced ejection fraction according to blood pressure: the GALACTIC-HF trial